The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Central Nervous System (CNS) Cancers provide interdisciplinary recommendations for managing adult CNS cancers. Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. These NCCN Guidelines Insights summarize the NCCN CNS Cancers Panel's discussion and highlight notable changes in the 2015 update. This article outlines the data and provides insight into panel decisions regarding adjuvant radiation and chemotherapy treatment options for high-risk newly diagnosed low-grade gliomas and glioblastomas. Additionally, it describes the panel's assessment of new data and the ongoing debate regarding the use of alternating electric field therapy for high-grade gliomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2015.0148 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Mutation in the Development of Eleven Different Cancers.
Cancers (Basel)
December 2024
Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA.
: With the rise in prevalence of diagnostic genetic techniques like RNA sequencing and whole exome sequencing (WES), as well as biological treatment regiments for cancer therapy, several genes have been implicated in carcinogenesis. This review aims to update our understanding of the Neurofibromatosis 2 (NF2) gene and its role in the pathogenesis of various cancers. : A comprehensive search of five online databases yielded 43 studies that highlighted the effect of sporadic NF2 mutations on several cancers, including sporadic meningioma, ependymoma, schwannoma, mesothelioma, breast cancer, hepatocellular carcinoma, prostate cancer, glioblastoma, thyroid cancer, and melanoma.
View Article and Find Full Text PDFStructure-Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2.
Molecules
December 2024
Institut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany.
The serine/threonine kinase CK2 (formerly known as casein kinase II) plays a crucial role in various CNS disorders and is highly expressed in various types of cancer. Therefore, inhibiting this key kinase could be promising for the treatment of these diseases. The CK2 holoenzyme is formed by the recruitment of two catalytically active CK2α and/or CK2α' subunits by a regulatory CK2β dimer.
View Article and Find Full Text PDFCurrent situation of central nervous system tumour survivors in a spanish hospital.
An Pediatr (Engl Ed)
January 2025
Departamento de Oncohematología Pediátrica, Hospital Universitario Niño Jesús, Madrid, Spain. Electronic address:
Introduction: Despite the increasing number of central nervous system (CNS) tumour survivors, long-term (LT) sequelae remain a substantial burden on their health through various life stages. The aim of our study was to evaluate late morbidity, health-related quality of life (HRQoL), self-esteem, functional status, adaptive behaviour, physical activity and social outcomes such as education, employment, relationship status and possession of a driver's license, in addition to the role of LT effects of radiotherapy (RTx) on these outcomes.
Methods: The study included 111 CNS tumour survivors with a minimum of 10 years of follow-up.
Carbon-based nanozymes for cancer therapy and diagnosis: A review.
Int J Biol Macromol
January 2025
Independent Researcher, W Nazar ST, Boostan Ave, Isfahan, Iran. Electronic address:
Carbon-based nanozymes (CNs) have emerged as a significant innovation in targeted cancer therapy, demonstrating great potential for advancing cancer diagnosis and treatment. With exceptional catalytic properties, remarkable biocompatibility, and the ability to precisely target cancer cells, CNs provide a promising avenue for the development of novel oncological therapies. By functionalizing their surfaces with targeting ligands, such as antibodies or peptides, CNs can specifically recognize and bind to cancer cells.
View Article and Find Full Text PDFClavulanic acid prevents paclitaxel-induced neuropathic pain through a systemic and central anti-inflammatory effect in mice.
Neurotherapeutics
January 2025
Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico. Electronic address:
Paclitaxel (PCX) based treatments, commonly used to treat breast, ovarian and lung cancers, have the highest incidence of chemotherapy-induced neuropathic pain, affecting from 38 to 94 % of patients. Unfortunately, analgesic treatments are not always effective for PCX-induced neuropathic pain (PINP). This study aimed to evaluate the antinociceptive effect of clavulanic acid (CLAV), a clinically used β-lactam molecule, in both therapeutic and preventive contexts in mice with PINP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!